XERS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
XERS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Xeris Biopharma Holdings's Dividend Payout Ratio for the months ended in Sep. 2024 was 0.00.
The historical rank and industry rank for Xeris Biopharma Holdings's Dividend Payout Ratio or its related term are showing as below:
As of today (2025-03-02), the Dividend Yield % of Xeris Biopharma Holdings is 0.00%.
Xeris Biopharma Holdings's Dividends per Share for the months ended in Sep. 2024 was $0.00.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
The historical data trend for Xeris Biopharma Holdings's Dividend Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xeris Biopharma Holdings Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Dividend Payout Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
Xeris Biopharma Holdings Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Dividend Payout Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Xeris Biopharma Holdings's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Xeris Biopharma Holdings's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where Xeris Biopharma Holdings's Dividend Payout Ratio falls into.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
Xeris Biopharma Holdings's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Dividend Payout Ratio | = | Dividends per Share (A: Dec. 2023 ) | / | EPS without NRI (A: Dec. 2023 ) |
= | 0 | / | -0.467 | |
= | N/A |
Xeris Biopharma Holdings's Dividend Payout Ratio for the quarter that ended in Sep. 2024 is calculated as
Dividend Payout Ratio | = | Dividends per Share (Q: Sep. 2024 ) | / | EPS without NRI (Q: Sep. 2024 ) |
= | 0 | / | -0.112 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xeris Biopharma Holdings (NAS:XERS) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Thank you for viewing the detailed overview of Xeris Biopharma Holdings's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
John P. Schmid | director | 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
Jeffrey W Sherman | director | C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618 |
Steven Pieper | officer: Chief Financial Officer | XERIS PHARMACEUTICALS, INC., 180 N. LASALLE STREET, SUITE 1600, CHICAGO IL 60601 |
Dawn Halkuff | director | C/O XERIS PHARMACEUTICALS, 180 N. LASALLE ST., STE. 1800, CHICAGO IL 60601 |
Shannon John Patrick Jr | officer: See Remarks | DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960 |
Paul R Edick | director, officer: See Remarks | C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010 |
Ricki Louise Fairley | director | XERIS BIOPHARMA HOLDINGS, INC., 180 N. LASALLE STREET, SUITE 1600, CHICAGO IL 60601 |
Steven Prestrelski | officer: Chief Scientific Officer | C/O XERIS PHARMACEUTICALS, 180 N. LASALLE STREET, SUITE 1800, CHICAGO IL 60601 |
Beth Hecht | officer: See Remarks | C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050 |
Kenneth Erland Johnson | officer: See Remarks | C/O XERIS PHARMACEUTICALS, INC., 180 N. LASALLE STREET, SUITE 1800, CHICAGO IL 60601 |
Barbara-jean Anne Bormann-kennedy | director | 1188 BROADWAY, SUITE 306, SOMERVILLE MA 02144 |
Marla Persky | director | ONE BAXTER PARKWAY, DEERFIELD IL 60015 |
John Johnson | director | DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101 |
Garheng Kong | director | 712 COLLEGE AVENUE, MENLO PARK CA 94025 |
Barry M. Deutsch | officer: See Remarks | OVATION PHARMACEUTICALS, INC. FOUR PARKWAY NORTH, SUITE 200 DEERFIELD IL 60015 |
From GuruFocus
By GuruFocus Research • 03-07-2024
By Business Wire • 11-08-2024
By PRNewswire • 01-21-2025
By Business Wire • 03-06-2024
By GuruFocus News • 11-08-2024
By Business Wire • 10-04-2024
By Business Wire • 02-05-2025
By Business Wire • 07-03-2024
By Business Wire • 11-26-2024
By GuruFocus Research • 05-10-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.